Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq

#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years @RheumNow https://t.co/vPflDm22b2 https://t.co/7Al9I3Eidu

Retrospective study of Apremilast survival in 281 #psoriasis pts(22% w/ PsA) showed 1 yr drug survival=54%, less at 2 yrs (41%), 3 yrs (32%), and 4 yrs (30%). Half 1+ adverse events; D/C mostly for lack of efficacy (27%), adverse events (12%) https://t.co/2dm6H6cYNX https://t.co/F2YtzzWMdT

Phase 3 trial of IV 200 mg qd hydrocortisone in 800 pts admitted to ICU for severe community-acquired pneumonia. Day 28 strongly favored IV Hydrocort vs PBO for mortality (6% v 12%; P=0.006), Mech ventilation (18% vs 29.5%), vasopressors (15% v 25%) https://t.co/TqxorRAuvc https://t.co/0R7kNaKgj5

#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/MZJfg2lM70 https://t.co/eOkcwd4xMz

The Biosimilar "Buy In" Dr. Rachel Tate, @uptotate , shared insights into these key discussions during RheumNow Live. https://t.co/dD3uZCNQEo https://t.co/MuN91Oqbvo

Metformin Reduces Osteoarthritis Risk Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported. https://t.co/dmyKssbWjO https://t.co/p7lPdjYfbU

Spondyloarthritis Innovations The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it. https://t.co/3JeNeE0EO6 https://t.co/fA1B2TA2xF

Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

FDA Approves Citrate-Free Formulation of Hyrimoz, a Biosimilar to Humira - but adalimumab-adaz HCF wont be available in USA until July 1, 2023 https://t.co/RRjxPW5I4O https://t.co/hf6NlkGG7W

Polypharmacy Increased in Psoriatic Arthritis Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA. https://t.co/vispc9ei51 https://t.co/s45Nmpf46P

A Pilot Trial of Anifrolumab in Discoid Lupus A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). https://t.co/8OZqRvD1Lv https://t.co/T7dWQWc1gX